22,567 reports of this reaction
4.7% of all SECUKINUMAB reports
#2 most reported adverse reaction
PSORIASIS is the #2 most commonly reported adverse reaction for SECUKINUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 22,567 FDA adverse event reports linking SECUKINUMAB to PSORIASIS. This represents approximately 4.7% of all 482,303 adverse event reports for this drug.
SECUKINUMAB has an overall safety score of 65 out of 100. Patients taking SECUKINUMAB who experience psoriasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIASIS is moderately reported among SECUKINUMAB users, representing a notable but not dominant share of adverse events.
In addition to psoriasis, the following adverse reactions have been reported for SECUKINUMAB:
The following drugs have also been linked to psoriasis in FDA adverse event reports:
PSORIASIS has been reported as an adverse event in 22,567 FDA reports for SECUKINUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIASIS accounts for approximately 4.7% of all adverse event reports for SECUKINUMAB, making it one of the most commonly reported side effect.
If you experience psoriasis while taking SECUKINUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.